Merck

ZERBAXA

Manufacturer:

Merck

Zerbaxa HCPCS:

J0695

HCPCS Code Descriptor:

Injection, ceftolozane 50 mg and tazobactam 25 mg

Category:

J Code

Zerbaxa NDCs:

67919-0030-01

Primary Type:

Antibiotic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zerbaxa:

ZERBAXA is an Antibiotic drug manufactured by Merck and administered via the Intravenous route of administration. The J Code: J0695 is aligned to the drug ZERBAXA.

ACCESS PRICING AND MORE BY REGISTERING

J0695 Added Date:

January 1, 2016

J0695 Effective Date:

January 1, 2016

J0695 Termination Date:

HCPCS Active

Zerbaxa billing and coding information can be found through Merck at the link below:
Zerbaxa patient assistance information can be found through The Merck Helps Program at the URL: https://www.merckhelps.com/
ZERBAXA prescribing information can be found at the link below:
Information regarding ZERBAXA’s side effects can be found at MedlinePlus